Active substances
Flumetasone pivalate + Salicylic acid
- SFDA 4
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| LOCASALEN OINT. | 0.02 , 3 % | Ointment · Topical | 1 Tube | SAR 46.65 | NCE · Prescription | AMDIPHARMA | Withdrawn by MAH · Not Marketed |
| LOCASALEN OINT. | 0.02 , 3 % | Ointment · Topical | 1 Tube | SAR 16.00 | NCE · Prescription | AMDIPHARMA | Withdrawn by MAH · Not Marketed |
| LOCASALEN OINT. | 0.02 , 3 % | Ointment · Topical | 1 Tube | SAR 16.00 | NCE · Prescription | NOVARTIS | Withdrawn by MAH · Not Marketed |
| LOCASALEN OINT. | 0.02 , 3 % | Ointment · Topical | 1 Tube | SAR 46.65 | NCE · Prescription | NOVARTIS | Withdrawn by MAH · Not Marketed |
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.